Table 1.
Relation between the GMI and other activity end-points.
| Categories | GMI < 1.0 (n = 177) | GMI=(1.00–1.33) (n = 21) | GMI > 1.33 (n = 81) | P value |
|---|---|---|---|---|
| PFS | ||||
| Censored | 18 (10.2%) | 2 (9.5%) | 21 (25.9%) | <0.0001* |
| Median PFS (months) | 1.8 | 3.2 | 7.6 | |
| PFS at 3 months | 29.6% | 52.4% | 82.6% | |
| PFS at 6 months | 12.3% | 28.6% | 56.8% | |
| Best objective response | ||||
| Assessable | 177 (100.0%) | 21 (100.0%) | 79 (97.5%) | <0.0001** |
| Progressive disease | 107 (60.5%) | 9 (42.9%) | 12 (14.8%) | |
| Stable disease | 67 (37.9%) | 12 (57.1%) | 50 (61.7%) | |
| Partial response | 3 (1.7%) | 0 | 17 (21.0%) | |
| Overall survival | ||||
| Censored | 24 (13.6%) | 3 (14.7%) | 16 (19.8%) | =0.0005* |
| Median OS (months) | 9.1 | 13.9 | 23.8 | |
| OS at 12 months | 44.7% | 57.1% | 76.5% | |
| OS at 24 months | 25.5% | 19.0% | 47.5% | |
| OS at 36 months | 11.8% | 14.3% | 21.3% | |
*Log-rank test; **Fisher's exact test.
GMI, growth modulation index; OS, overall survival; PFS, progression-free survival.